Antiepileptic Drugs and Markers of Vascular Risk
Tóm tắt
Từ khóa
Tài liệu tham khảo
Annegers JF, Hauser WA, Shirts SB: Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 1984, 25:699–704.
Nilsson L, Tomson T, Farahmand BY, et al.: Cause-specific mortality in epilepsy: a cohort study of more than 9, 000 patients once hospitalized for epilepsy. Epilepsia 1997, 38:1062–1068.
Ding D, Wang W, Wu J, et al.: Premature mortality in people with epilepsy in rural China: a prospective study. Lancet Neurol 2006, 5:823–827.
Satishchandra P, Chandra V, Schoenberg BS: Case-control study of associated conditions at the time of death in patients with epilepsy. Neuroepidemiology 1988, 7:109–114.
Gaitatzis A, Carroll K, Majeed A, Sander JW: The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004, 45:1613–1622.
Cockerell OC, Johnson AL, Sander JW, et al.: Mortality from epilepsy: results from a prospective population-based study. Lancet 1994, 344:918–921.
Muuronen A, Kaste M, Nikkila EA, Tolppanen EM: Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J (Clin Res Ed) 1985, 291:1481–1483.
Nakken KO, Kornstad S: Do males 30–50 years of age with chronic epilepsy and on long-term anticonvulsant medication have lower-than-expected risk of developing coronary heart disease? Epilepsia 1998, 39:326–330.
Gibbons GF: The role of cytochrome P450 in the regulation of cholesterol biosynthesis. Lipids 2002, 37:1163–1170.
Kandutsch AA, Chen HW: Inhibition of cholesterol synthesis by oxygenated sterols. Lipids 1978, 13:704–707.
Franzoni E, Govoni M, D’Addato S, et al.: Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992, 33:932–935.
Eiris JM, Lojo S, Del Rio MC, et al.: Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995, 45:1155–1157.
Eirís J, Novo-Rodríguez MI, Del Río M, et al.: The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000, 41:1–7.
Castro-Gago M, Novo-Rodriguez MI, Blanco-Barca MO, et al.: Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital. J Child Neurol 2006, 21:48–53.
Verrotti A, Domizio S, Angelozzi B, et al.: Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health 1997, 33:242–245.
Verrotti A, Basciani F, Domizio S, et al.: Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 1998, 19:364–367.
Voudris KA, Attilakos A, Katsarou E, et al.: Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res 2006, 70:211–217.
Demircioglu S, Soylu A, Dirik E: Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children. Pediatr Neurol 2000, 23:142–146.
Nikolaos T, Stylianos G, Chryssoula N, et al.: The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004, 10:MT50–MT52.
Aggarwal A, Singh V, Batra S, et al.: Effect of carbamazepine therapy on serum lipids in children with partial epilepsy. Pediatr Neurol 2009, 40:94–97.
Bramswig S, Sudhop T, Luers C, et al.: Lipoprotein(a) concentration increases during treatment with carbamazepine. Epilepsia 2003, 44:457–460.
Isojarvi JI, Pakarinen AJ, Myllyla VV: Serum lipid levels during carbamazepine medication. A prospective study. Arch Neurol 1993, 50:590–593.
Luoma PV, Sotaniemi EA, Pelkonen RO, Pirttiaho HI: Serum low-density lipoprotein and high-density lipoprotein cholesterol, and liver size in subjects on drugs inducing hepatic microsomal enzymes. Eur J Clin Pharmacol 1985, 28:615–618.
Calandre EP, Sinues Porta B, Garcia de la Calzada D: The effect of chronic phenytoin treatment on serum lipid profile in adult epileptic patients. Epilepsia 1992, 33:154–157.
Mintzer S, Skidmore CT, Abidin CJ, et al.: Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009, 65:448–456. This study directly compared the effects of inducing AEDs on various serologic markers to those of non-inducing AEDs. This is the first study to examine CRP in patients with epilepsy or in any AED-treated population.
Sonmez FM, Demir E, Orem A, et al.: Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol 2006, 21:70–74.
Reddy MN: Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med 1985, 180:359–363.
Isojarvi JI, Pakarinen AJ, Rautio A, et al.: Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994, 35:1217–1220.
Calandre EP, Rodriquez-Lopez C, Blazquez A, Cano D: Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand 1991, 83:250–253.
The Emerging Risk Factors Collaboration: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412–423.
Miller M, Burgan RG, Osterlund L, et al.: A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Arterioscler Thromb Vasc Biol 1995, 15:2151–2156.
Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979.
Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.
Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14, 719 initially healthy American women. Circulation 2003, 107:391–397.
Tan TY, Lu CH, Chuang HY, et al.: Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 2009, 50:1579–1586. This study measured CA-IMT in patients on long-term AED therapy. Although limited by lack of data on individual AEDs, it clearly links AED use with the development of atherosclerosis.
McIlroy SP, Dynan KB, Lawson JT, et al.: Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002, 33:2351–2356.
Karabiber H, Sonmezgoz E, Ozerol E, et al.: Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev 2003, 25:113–115.
Apeland T, Mansoor MA, Strandjord RE: Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res 2001, 47:27–35.
Belcastro V, Striano P, Gorgone G, et al.: Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia 2010, 51:274–279. This cross-sectional study confirms earlier findings of HCY elevations with enzyme-inducing drugs and also makes a new association between elevated HCY and the newer-generation, weakly enzyme-inducing agents oxcarbazepine and topiramate.
Verrotti A, Pascarella R, Trotta D, et al.: Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res 2000, 41:253–257.
Attilakos A, Papakonstantinou E, Schulpis K, et al.: Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res 2006, 71:229–232.
Gidal BE, Tamura T, Hammer A, Vuong A: Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. Epilepsy Res 2005, 64:161–166.
Huemer M, Ausserer B, Graninger G, et al.: Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation. Epilepsia 2005, 46:1677–1683.
Jallon P, Picard F: Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001, 24:969–978.
Kim JY, Lee HW: Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007, 48:1366–1370.
Verrotti A, Manco R, Agostinelli S, et al.: The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010, 51:268–273.
Pylvanen V, Knip M, Pakarinen AJ, et al.: Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003, 60:571–574.
O’Leary DH, Polak JF, Kronmal RA, et al.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14–22.
Lorenz MW, von Kegler S, Steinmetz H, et al.: Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006, 37:87–92.
Silvestrini M, Cagnetti C, Pasqualetti P, et al.: Carotid wall thickness and stroke risk in patients with asymptomatic internal carotid stenosis. Atherosclerosis 2010 Jan 4 (Epub ahead of print).
Schwaninger M, Ringleb P, Annecke A, et al.: Elevated plasma concentrations of lipoprotein(a) in medicated epileptic patients. J Neurol 2000, 247:687–690.
Hamed SA, Hamed EA, Hamdy R, Nabeshima T: Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res 2007, 74:183–192.